HC Wainwright Has Optimistic Outlook of AUPH FY2025 Earnings

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Equities researchers at HC Wainwright boosted their FY2025 earnings per share estimates for Aurinia Pharmaceuticals in a research note issued on Wednesday, November 5th. HC Wainwright analyst A. He now forecasts that the biotechnology company will post earnings of $0.74 per share for the year, up from their prior forecast of $0.65. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share. HC Wainwright also issued estimates for Aurinia Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS, Q1 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.15 EPS and FY2026 earnings at $0.64 EPS.

A number of other research firms have also commented on AUPH. Bloom Burton lowered shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $10.00 to $21.00 in a report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday. Two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $17.67.

Aurinia Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ:AUPH opened at $13.95 on Friday. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1.84 billion, a PE ratio of 32.44 and a beta of 1.30. Aurinia Pharmaceuticals has a 1 year low of $6.55 and a 1 year high of $16.20. The firm has a fifty day moving average price of $12.22 and a 200 day moving average price of $10.12.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.07. The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,744 shares during the period. MAI Capital Management acquired a new position in Aurinia Pharmaceuticals in the 1st quarter valued at approximately $39,000. DekaBank Deutsche Girozentrale acquired a new position in Aurinia Pharmaceuticals in the 1st quarter valued at approximately $60,000. Xponance Inc. bought a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter worth approximately $82,000. Finally, Kazazian Asset Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $84,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.